Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Kineta ( (KANT) ) just unveiled an announcement.
Kineta, Inc. and TuHURA Biosciences have entered into a non-binding letter of intent for a potential transaction where TuHURA would acquire rights to Kineta’s VISTA blocking antibody, KVA12123. This potential acquisition aligns with TuHURA’s strategy of expanding its immune-oncology pipeline, which includes novel therapies like IFx-2.0 and IFx-3.0 targeting various cancers. TuHURA aims to achieve several milestones in 2024 and 2025, including initiating Phase 3 trials and completing the acquisition, enhancing its position in the biotechnology sector.
For detailed information about KANT stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Shareholder Alert for Chipotle Mexican Grill, Inc. (NYSE:CMG)
- 3 Penny Stocks to Watch Now, 11/26/24
- Rivian Gets Conditional DOE Loan of $6.6B for Georgia Plant
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
